A randomized trial comparing safety, immunogenicity and efficacy of self-amplifying mRNA and adenovirus-vector COVID-19 vaccines

A randomized trial comparing safety, immunogenicity and efficacy of self-amplifying mRNA and adenovirus-vector COVID-19 vaccines

Abstract This phase 3 trial compared safety, tolerability, immunogenicity and efficacy of the self-amplifying mRNA COVID-19 vaccine, ARCT-154, with ChAdOx1-S adenovirus-vector vaccine. In four centers in Vietnam adult participants aged 18‒85 years were randomly assigned to receive two doses, 28 days...

Full description

Bibliographic Details
Main Authors: Nhan Thi Ho, Steve G. Hughes, Rose Sekulovich, Van Thanh Ta, Thuong Vu Nguyen, Anh Thi Van Pham, Quang Chan Luong, Ly Thi Le Tran, Anh Thi Van Luu, Anh Ngoc Nguyen, Ha Thai Pham, Van Thu Nguyen, Dina Berdieva, Roberto Bugarini, Xuexuan Liu, Carole Verhoeven, Igor Smolenov, Xuan-Hung Nguyen
Format: Article
Language:English
Published: Nature Portfolio 2024-11-01
Series:npj Vaccines
Online Access:https://doi.org/10.1038/s41541-024-01017-5

Internet

https://doi.org/10.1038/s41541-024-01017-5

Similar Items